Back

Lesson learned from the COMPASS and VOYAGER PAD trials: dual pathway inhibition as a new antithrombotic paradigm?

European Journal of Preventive Cardiology

6 September 2021
Organised by: Logo
Read full article
ESC Journals

Contributors

Stefania Basili
Stefania Basili

Author

Sapienza University of Rome Rome , Italy

Giulio Francesco Romiti
Giulio Francesco Romiti

Author

Sapienza University of Rome Rome , Italy

Roberto Cangemi
Roberto Cangemi

Author

Bernadette Corica
Bernadette Corica

Author

You may be interested in
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
19 July 2023
thumbnail
Congress Presentation
Pharmacodynamic effects of vorapaxar as an add-on antiplatelet therapy in patients with and without diabetes mellitus: the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-5 study
1 September 2019
thumbnail
Congress Presentation
Dual pathway inhibitor therapy switched from dual antiplatelet therapy reduces risk of recurrent in-stent occlusion after endovascular therapy for femoropopliteal in-stent occlusion.
26 August 2023
thumbnail
Congress Session
How can targeting FXI(a) advance antithrombotic therapy for stroke prevention?
27 August 2023

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources